Opinion|Videos|November 28, 2023
Practical Considerations for Zenocutuzumab in NRG1 Fusion–Positive Malignancies
Drs Macarulla and Neuzillet discuss the role of zenocutuzumab in the treatment of patients with NRG1 fusion–positive solid tumors.
Advertisement
Episodes in this series
Educational support for this activity provided by Merus.
Advertisement
Related to this article
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
Subcutaneous Isatuximab Enhances Patient Experience in Multiple Myeloma
5